129 related articles for article (PubMed ID: 37146157)
1. PPARγ Corepression Involves Alternate Ligand Conformation and Inflation of H12 Ensembles.
Frkic RL; Pederick JL; Horsfall AJ; Jovcevski B; Crame EE; Kowalczyk W; Pukala TL; Chang MR; Zheng J; Blayo AL; Abell AD; Kamenecka TM; Harbort JS; Harmer JR; Griffin PR; Bruning JB
ACS Chem Biol; 2023 May; 18(5):1115-1123. PubMed ID: 37146157
[TBL] [Abstract][Full Text] [Related]
2. A structural mechanism for directing corepressor-selective inverse agonism of PPARγ.
Brust R; Shang J; Fuhrmann J; Mosure SA; Bass J; Cano A; Heidari Z; Chrisman IM; Nemetchek MD; Blayo AL; Griffin PR; Kamenecka TM; Hughes TS; Kojetin DJ
Nat Commun; 2018 Nov; 9(1):4687. PubMed ID: 30409975
[TBL] [Abstract][Full Text] [Related]
3. Biochemical and structural basis for the pharmacological inhibition of nuclear hormone receptor PPARγ by inverse agonists.
Irwin S; Karr C; Furman C; Tsai J; Gee P; Banka D; Wibowo AS; Dementiev AA; O'Shea M; Yang J; Lowe J; Mitchell L; Ruppel S; Fekkes P; Zhu P; Korpal M; Larsen NA
J Biol Chem; 2022 Nov; 298(11):102539. PubMed ID: 36179791
[TBL] [Abstract][Full Text] [Related]
4. A molecular switch regulating transcriptional repression and activation of PPARγ.
Shang J; Mosure SA; Zheng J; Brust R; Bass J; Nichols A; Solt LA; Griffin PR; Kojetin DJ
Nat Commun; 2020 Feb; 11(1):956. PubMed ID: 32075969
[TBL] [Abstract][Full Text] [Related]
5. Conformational Diversity of the Helix 12 of the Ligand Binding Domain of PPARγ and Functional Implications.
Batista MR; Martínez L
J Phys Chem B; 2015 Dec; 119(50):15418-29. PubMed ID: 26598113
[TBL] [Abstract][Full Text] [Related]
6. PPARγ in Complex with an Antagonist and Inverse Agonist: a Tumble and Trap Mechanism of the Activation Helix.
Frkic RL; Marshall AC; Blayo AL; Pukala TL; Kamenecka TM; Griffin PR; Bruning JB
iScience; 2018 Feb; 5():69-79. PubMed ID: 30123887
[TBL] [Abstract][Full Text] [Related]
7. Structural insight into PPARgamma activation through covalent modification with endogenous fatty acids.
Waku T; Shiraki T; Oyama T; Fujimoto Y; Maebara K; Kamiya N; Jingami H; Morikawa K
J Mol Biol; 2009 Jan; 385(1):188-99. PubMed ID: 18977231
[TBL] [Abstract][Full Text] [Related]
8. Insights into Dynamic Mechanism of Ligand Binding to Peroxisome Proliferator-Activated Receptor γ toward Potential Pharmacological Applications.
Miyamae Y
Biol Pharm Bull; 2021; 44(9):1185-1195. PubMed ID: 34471046
[TBL] [Abstract][Full Text] [Related]
9. Medium chain fatty acids are selective peroxisome proliferator activated receptor (PPAR) γ activators and pan-PPAR partial agonists.
Liberato MV; Nascimento AS; Ayers SD; Lin JZ; Cvoro A; Silveira RL; Martínez L; Souza PC; Saidemberg D; Deng T; Amato AA; Togashi M; Hsueh WA; Phillips K; Palma MS; Neves FA; Skaf MS; Webb P; Polikarpov I
PLoS One; 2012; 7(5):e36297. PubMed ID: 22649490
[TBL] [Abstract][Full Text] [Related]
10. The optimal corepressor function of nuclear receptor corepressor (NCoR) for peroxisome proliferator-activated receptor γ requires G protein pathway suppressor 2.
Guo C; Li Y; Gow CH; Wong M; Zha J; Yan C; Liu H; Wang Y; Burris TP; Zhang J
J Biol Chem; 2015 Feb; 290(6):3666-79. PubMed ID: 25519902
[TBL] [Abstract][Full Text] [Related]
11. PPARγ helix 12 exhibits an antagonist conformation.
Fratev F
Phys Chem Chem Phys; 2016 Apr; 18(13):9272-80. PubMed ID: 26975214
[TBL] [Abstract][Full Text] [Related]
12. Structural basis for differential activities of enantiomeric PPARγ agonists: Binding of S35 to the alternate site.
Jang JY; Koh M; Bae H; An DR; Im HN; Kim HS; Yoon JY; Yoon HJ; Han BW; Park SB; Suh SW
Biochim Biophys Acta Proteins Proteom; 2017 Jun; 1865(6):674-681. PubMed ID: 28342850
[TBL] [Abstract][Full Text] [Related]
13. Defining a conformational ensemble that directs activation of PPARγ.
Chrisman IM; Nemetchek MD; de Vera IMS; Shang J; Heidari Z; Long Y; Reyes-Caballero H; Galindo-Murillo R; Cheatham TE; Blayo AL; Shin Y; Fuhrmann J; Griffin PR; Kamenecka TM; Kojetin DJ; Hughes TS
Nat Commun; 2018 May; 9(1):1794. PubMed ID: 29728618
[TBL] [Abstract][Full Text] [Related]
14. A novel partial agonist of peroxisome proliferator-activated receptor-gamma (PPARgamma) recruits PPARgamma-coactivator-1alpha, prevents triglyceride accumulation, and potentiates insulin signaling in vitro.
Burgermeister E; Schnoebelen A; Flament A; Benz J; Stihle M; Gsell B; Rufer A; Ruf A; Kuhn B; Märki HP; Mizrahi J; Sebokova E; Niesor E; Meyer M
Mol Endocrinol; 2006 Apr; 20(4):809-30. PubMed ID: 16373399
[TBL] [Abstract][Full Text] [Related]
15. The nuclear receptor PPARγ individually responds to serotonin- and fatty acid-metabolites.
Waku T; Shiraki T; Oyama T; Maebara K; Nakamori R; Morikawa K
EMBO J; 2010 Oct; 29(19):3395-407. PubMed ID: 20717101
[TBL] [Abstract][Full Text] [Related]
16. Molecular dynamics simulations for human CAR inverse agonists.
Jyrkkärinne J; Küblbeck J; Pulkkinen J; Honkakoski P; Laatikainen R; Poso A; Laitinen T
J Chem Inf Model; 2012 Feb; 52(2):457-64. PubMed ID: 22233089
[TBL] [Abstract][Full Text] [Related]
17. Structural studies unravel the active conformation of apo RORγt nuclear receptor and a common inverse agonism of two diverse classes of RORγt inhibitors.
Li X; Anderson M; Collin D; Muegge I; Wan J; Brennan D; Kugler S; Terenzio D; Kennedy C; Lin S; Labadia ME; Cook B; Hughes R; Farrow NA
J Biol Chem; 2017 Jul; 292(28):11618-11630. PubMed ID: 28546429
[TBL] [Abstract][Full Text] [Related]
18. Ligand-Dependent Corepressor (LCoR) Is a Rexinoid-Inhibited Peroxisome Proliferator-Activated Receptor γ-Retinoid X Receptor α Coactivator.
Shalom-Barak T; Liersemann J; Memari B; Flechner L; Devor CE; Bernardo TM; Kim S; Matsumoto N; Friedman SL; Evans RM; White JH; Barak Y
Mol Cell Biol; 2018 May; 38(9):. PubMed ID: 29463649
[TBL] [Abstract][Full Text] [Related]
19. Definition of functionally and structurally distinct repressive states in the nuclear receptor PPARγ.
Heidari Z; Chrisman IM; Nemetchek MD; Novick SJ; Blayo AL; Patton T; Mendes DE; Diaz P; Kamenecka TM; Griffin PR; Hughes TS
Nat Commun; 2019 Dec; 10(1):5825. PubMed ID: 31862968
[TBL] [Abstract][Full Text] [Related]
20. LT175 is a novel PPARα/γ ligand with potent insulin-sensitizing effects and reduced adipogenic properties.
Gilardi F; Giudici M; Mitro N; Maschi O; Guerrini U; Rando G; Maggi A; Cermenati G; Laghezza A; Loiodice F; Pochetti G; Lavecchia A; Caruso D; De Fabiani E; Bamberg K; Crestani M
J Biol Chem; 2014 Mar; 289(10):6908-6920. PubMed ID: 24451380
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
